# RiboPro

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ribopro

- Industry: Biopolymers
- Headquarters: Netherlands
- Website: www.ribopro.eu
- Latest round: Series A (Oct 31, 2024)
- Investors on record: 4

## About

Based in the Netherlands, RiboPro specializes in advancing RNA-based therapeutics through the development and manufacturing of messenger RNA (mRNA) and lipid nanoparticle (LNP) formulations.RiboPro, founded in 2020 in the Netherlands, focuses on RNA-based therapeutics. The company is led by Alexander Van Asbeck, who serves as the CEO. RiboPro has completed one deal to date, with its most recent deal occurring on October 31, 2024.RiboPro specializes in the development and manufacturing of messenger RNA (mRNA) and lipid nanoparticle (LNP) formulations aimed at advancing RNA-based therapeutics. Their core offerings encompass custom mRNA design, GMP-grade manufacturing, and formulation services, facilitating the creation of targeted mRNA therapeutics for various medical applications, including chronic kidney disease, eye diseases, and immunotherapy. RiboPro's technologies are utilized by a diverse clientele, including biopharma companies, research institutions, and health networks across multiple geographical markets, including Europe, the United States, Japan, and South Korea. By providing a comprehensive suite of services that ranges from experimental design to regulatory support, RiboPro positions itself as a one-stop shop for mRNA therapy pioneers, ensuring high-quality products tailored to meet the specific needs of its customers.RiboPro generates revenue through a business model that primarily involves direct partnerships with clients in the biopharmaceutical sector. Transactions are structured around the provision of custom mRNA and LNP formulations, with clients engaging RiboPro for both one-off projects and long-term collaborations that may include contract research and development agreements. The company’s revenue streams are derived from various services, including the manufacture of high-quality mRNA for research and therapeutic applications, which are sold to academic institutions, biotechnology firms, and healthcare organizations. Additionally, the pricing structure reflects the complexity and customization of the products, with clients benefiting from tailored services, priority manufacturing, and access to proprietary technologies. As a result, RiboPro is positioned to support a wide range of projects, from initial research phases to advanced therapeutic applications.In October 2024, RiboPro raised an undisclosed amount of venture funding from new investor Mountainview Capital Partners, with participation from returning investors Rockstart, BOM Brabant Ventures, and Vlasroot. The company will use the funding to provide additional solutions in the healthcare industry. RiboPro aims to expand its product offerings with new mRNA formulations targeted for release by mid-2025, while also exploring growth opportunities in new geographical markets, including Asia and North America, by 2026.

## Funding rounds

- Series A, Oct 31, 2024 — Rockstart Enterprises, BOM Brabant Ventures, Mountainview Capital Partners, Vlasroot

## Investors

- Rockstart Enterprises (https://capitalatlas.ai/funds/rockstart-enterprises) — Series A
- BOM Brabant Ventures (https://capitalatlas.ai/funds/bom-brabant-ventures) — Series A
- Mountainview Capital Partners (https://capitalatlas.ai/funds/mountainview-capital-partners) — Series A
- Vlasroot — Series A